Beta-HCG Stimulation Test Dose for Cryptorchidism
The hCG stimulation test should NOT be routinely used for cryptorchidism management, but when performed for diagnostic purposes (evaluating anorchia in bilateral nonpalpable testes), use a single dose of 100 IU/kg or 5,000 IU/1.7 m² intramuscularly, with testosterone measurement 72-96 hours post-injection 1, 2.
Critical Context: hCG Is Not Recommended for Treatment
Before discussing dosing, it's essential to understand that providers should not use hormonal therapy to induce testicular descent as evidence shows low response rates (6-38% in controlled studies) and lack of long-term efficacy 1. The AUA guideline explicitly states this as a Standard recommendation with Grade B evidence 1. Success rates are poor (7% complete descent in one study), primarily due to anatomical barriers including abnormal gubernacular attachments (83% of cases), short testicular vessels, and closed internal rings 3.
When hCG Testing Is Appropriate
The hCG stimulation test has a diagnostic role only in evaluating boys with bilateral nonpalpable testes to distinguish between anorchia and functioning testicular tissue 1. The test assesses Leydig cell function, not as a therapeutic intervention.
Specific Dosing Protocols
Single-Dose Regimen (Preferred for Diagnosis)
For prepubertal boys:
- 100 IU/kg (maximum 5,000 IU) OR
- 5,000 IU/1.7 m² body surface area
- Route: Intramuscular
- Timing: Single injection
- Blood sampling: 72-96 hours post-injection for testosterone and dihydrotestosterone 2
This single-dose protocol is practical, reliable, and cost-saving compared to multi-dose regimens 2. Research demonstrates that a single dose produces a 22-35-fold increase in testosterone from baseline, with no significant difference between 72 and 96-hour measurements 2.
Alternative Multi-Dose Regimens (If Used)
The FDA label provides multiple dosing options for cryptorchidism (though again, not recommended for treatment) 4:
- 4,000 IU three times weekly for 3 weeks
- 5,000 IU every second day for 4 injections
- 500-1,000 IU three times weekly for 4-6 weeks
- Age-adjusted: 500 IU (< 1 year), 1,000 IU (1-10 years), 1,500 IU (> 10 years) daily for 3 consecutive days 5
However, single-dose testing is superior because repeated doses do not significantly improve diagnostic accuracy in prepubertal boys and add unnecessary complexity 6.
Interpretation of Results
- Positive response: Testosterone increase indicates functioning Leydig cells; testicular tissue is present
- No response: Combined with elevated FSH/LH and undetectable MIS/inhibin B suggests anorchia 1
- Quantitative differences: Higher testosterone responses (median pre/post ratio 11.4) correlate with normal-volume intra-abdominal testes versus dysplastic testes (ratio 4.0) 5
Important Caveat
Failure to respond to hCG alone is NOT diagnostic of anorchia—testicular dysgenesis with undescended testes may also fail to respond 1. The test must be confirmed with elevated FSH/LH and undetectable MIS/inhibin B 1.
Age-Specific Considerations
- Prepubertal boys: Show maximal relative testosterone response (70-fold increase) but smallest absolute increases due to limited Leydig cell mass 7
- Early pubertal boys: Demonstrate 6-fold increase with emergence of estradiol and 17-hydroxyprogesterone responses 7
- Optimal testing age: Between 4-9 years when typically instituted 4
Modern Alternative
Recombinant hCG (rhCG) 250 mcg subcutaneously is a promising alternative to urinary hCG, with blood sampling 7 days post-injection showing significant increases in testosterone, DHT, inhibin B, and AMH 8. This may become the preferred agent as urinary hCG becomes unavailable.
The Bottom Line for Clinical Practice
Do not use hCG to treat cryptorchidism—refer for surgical orchidopexy by 18 months of age 1. Surgery has >96% success rates with <2% testicular atrophy 1. Reserve hCG stimulation testing exclusively for diagnostic evaluation of bilateral nonpalpable testes using a single dose of 100 IU/kg or 5,000 IU/1.7 m² IM with 72-96 hour testosterone measurement 2.